vs
Side-by-side financial comparison of AbbVie (ABBV) and Accenture (ACN). Click either name above to swap in a different company.
Accenture is the larger business by last-quarter revenue ($18.0B vs $15.0B, roughly 1.2× AbbVie). Accenture runs the higher net margin — 10.1% vs 4.6%, a 5.5% gap on every dollar of revenue. On growth, AbbVie posted the faster year-over-year revenue change (9.9% vs 8.3%). Over the past eight quarters, Accenture's revenue compounded faster (4.7% CAGR vs 1.8%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Accenture plc is a Irish technology consulting company headquartered in Dublin, Ireland. Founded in 1989, Accenture provides information technology and management consulting services across 120 countries globally.
ABBV vs ACN — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0B | $18.0B |
| Net Profit | $697.0M | $1.8B |
| Gross Margin | — | 30.3% |
| Operating Margin | 26.6% | 13.8% |
| Net Margin | 4.6% | 10.1% |
| Revenue YoY | 9.9% | 8.3% |
| Net Profit YoY | -46.0% | 2.1% |
| EPS (diluted) | $0.39 | $2.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $15.0B | $18.0B | ||
| Q4 25 | $16.6B | $18.7B | ||
| Q3 25 | $15.8B | $17.6B | ||
| Q2 25 | $15.4B | $17.7B | ||
| Q1 25 | $13.3B | $16.7B | ||
| Q4 24 | $15.1B | $17.7B | ||
| Q3 24 | $14.5B | $16.4B | ||
| Q2 24 | $14.5B | $16.5B |
| Q1 26 | $697.0M | $1.8B | ||
| Q4 25 | $1.8B | $2.2B | ||
| Q3 25 | $186.0M | $1.4B | ||
| Q2 25 | $938.0M | $2.2B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $-22.0M | $2.3B | ||
| Q3 24 | $1.6B | $1.7B | ||
| Q2 24 | $1.4B | $1.9B |
| Q1 26 | — | 30.3% | ||
| Q4 25 | 72.6% | 33.1% | ||
| Q3 25 | 66.4% | 31.9% | ||
| Q2 25 | 71.8% | 32.9% | ||
| Q1 25 | 70.0% | 29.9% | ||
| Q4 24 | 70.9% | 32.9% | ||
| Q3 24 | 70.9% | 32.5% | ||
| Q2 24 | 70.9% | 33.4% |
| Q1 26 | 26.6% | 13.8% | ||
| Q4 25 | 27.3% | 15.3% | ||
| Q3 25 | 12.1% | 11.6% | ||
| Q2 25 | 31.7% | 16.8% | ||
| Q1 25 | 28.0% | 13.5% | ||
| Q4 24 | -9.9% | 16.7% | ||
| Q3 24 | 26.5% | 14.3% | ||
| Q2 24 | 27.6% | 16.0% |
| Q1 26 | 4.6% | 10.1% | ||
| Q4 25 | 10.9% | 11.8% | ||
| Q3 25 | 1.2% | 8.0% | ||
| Q2 25 | 6.1% | 12.4% | ||
| Q1 25 | 9.6% | 10.7% | ||
| Q4 24 | -0.1% | 12.9% | ||
| Q3 24 | 10.8% | 10.3% | ||
| Q2 24 | 9.5% | 11.7% |
| Q1 26 | $0.39 | $2.93 | ||
| Q4 25 | $1.02 | $3.54 | ||
| Q3 25 | $0.10 | $2.25 | ||
| Q2 25 | $0.52 | $3.49 | ||
| Q1 25 | $0.72 | $2.82 | ||
| Q4 24 | $-0.03 | $3.59 | ||
| Q3 24 | $0.88 | $2.67 | ||
| Q2 24 | $0.77 | $3.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $9.4B |
| Total DebtLower is stronger | — | $5.0B |
| Stockholders' EquityBook value | — | $31.2B |
| Total Assets | — | $67.1B |
| Debt / EquityLower = less leverage | — | 0.16× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $9.4B | ||
| Q4 25 | $5.3B | $9.7B | ||
| Q3 25 | $5.7B | $11.5B | ||
| Q2 25 | $6.5B | $9.6B | ||
| Q1 25 | $5.2B | $8.5B | ||
| Q4 24 | $5.6B | $8.3B | ||
| Q3 24 | $7.3B | $5.0B | ||
| Q2 24 | $13.2B | $5.5B |
| Q1 26 | — | $5.0B | ||
| Q4 25 | $58.9B | $5.0B | ||
| Q3 25 | $63.0B | $5.0B | ||
| Q2 25 | $63.0B | $5.0B | ||
| Q1 25 | $64.5B | $5.0B | ||
| Q4 24 | $60.3B | $5.0B | ||
| Q3 24 | $58.5B | $78.6M | ||
| Q2 24 | $58.0B | $68.9M |
| Q1 26 | — | $31.2B | ||
| Q4 25 | $-3.3B | $30.9B | ||
| Q3 25 | $-2.6B | $31.2B | ||
| Q2 25 | $-183.0M | $30.6B | ||
| Q1 25 | $1.4B | $29.2B | ||
| Q4 24 | $3.3B | $29.2B | ||
| Q3 24 | $6.0B | $28.3B | ||
| Q2 24 | $6.8B | $27.7B |
| Q1 26 | — | $67.1B | ||
| Q4 25 | $134.0B | $64.7B | ||
| Q3 25 | $133.9B | $65.4B | ||
| Q2 25 | $137.2B | $63.4B | ||
| Q1 25 | $136.2B | $59.9B | ||
| Q4 24 | $135.2B | $59.9B | ||
| Q3 24 | $143.4B | $55.9B | ||
| Q2 24 | $141.9B | $54.1B |
| Q1 26 | — | 0.16× | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.16× | ||
| Q1 25 | 45.44× | 0.17× | ||
| Q4 24 | 18.15× | 0.17× | ||
| Q3 24 | 9.70× | 0.00× | ||
| Q2 24 | 8.56× | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $3.8B |
| Free Cash FlowOCF − Capex | — | $3.7B |
| FCF MarginFCF / Revenue | — | 20.3% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.5B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.8B | ||
| Q4 25 | $5.2B | $1.7B | ||
| Q3 25 | $7.0B | $3.9B | ||
| Q2 25 | $5.2B | $3.7B | ||
| Q1 25 | $1.6B | $2.9B | ||
| Q4 24 | $7.0B | $1.0B | ||
| Q3 24 | $5.4B | $3.4B | ||
| Q2 24 | $2.3B | $3.1B |
| Q1 26 | — | $3.7B | ||
| Q4 25 | $4.9B | $1.5B | ||
| Q3 25 | $6.6B | $3.8B | ||
| Q2 25 | $4.9B | $3.5B | ||
| Q1 25 | $1.4B | $2.7B | ||
| Q4 24 | $6.8B | $870.3M | ||
| Q3 24 | $5.2B | $3.2B | ||
| Q2 24 | $2.0B | $3.0B |
| Q1 26 | — | 20.3% | ||
| Q4 25 | 29.4% | 8.0% | ||
| Q3 25 | 42.1% | 21.6% | ||
| Q2 25 | 31.7% | 19.8% | ||
| Q1 25 | 10.5% | 16.1% | ||
| Q4 24 | 44.7% | 4.9% | ||
| Q3 24 | 35.9% | 19.4% | ||
| Q2 24 | 14.0% | 18.3% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | 2.0% | 0.8% | ||
| Q3 25 | 2.4% | 0.6% | ||
| Q2 25 | 1.7% | 1.0% | ||
| Q1 25 | 1.8% | 1.0% | ||
| Q4 24 | 1.9% | 0.9% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 1.7% | 0.8% |
| Q1 26 | — | 2.09× | ||
| Q4 25 | 2.87× | 0.75× | ||
| Q3 25 | 37.76× | 2.77× | ||
| Q2 25 | 5.49× | 1.68× | ||
| Q1 25 | 1.27× | 1.60× | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | 3.49× | 2.01× | ||
| Q2 24 | 1.66× | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABBV
Segment breakdown not available.
ACN
| Products | $5.5B | 30% |
| Health And Public Service | $3.7B | 20% |
| Financial Services Sector | $3.4B | 19% |
| Communications Media And Technology | $3.1B | 17% |
| Resources | $2.4B | 13% |
